Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13744675 | 0.87 | AKR1B1 (0.53) | HPGDCYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL4214266 | 0.86 | CYP2C19 (0.53) | CA2HPGDCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL13744671 | 0.82 | HPGD (0.53) | HPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL13744662 | 0.82 | TP53 (0.50) | CA2HPGDCYP2C19MEN1KMT2A | |
| SCHEMBL13744508 | 0.82 | MEN1 (0.43) | CA2HPGDCYP2C19MEN1KMT2A | |
| SCHEMBL4223601 | 0.82 | TP53 (0.50) | HPGDCYP1A2CYP2C19KMT2AL3MBTL1 | |
| SCHEMBL4223833 | 0.82 | TP53 (0.54) | CA2HPGDCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL13744864 | 0.80 | HSD17B10 (0.54) | CA2HPGDCYP3A4KMT2AL3MBTL1 | |
| SCHEMBL13744520 | 0.79 | TP53 (0.59) | HPGDCYP1A2CYP3A4CYP2C19MEN1 | |
| SCHEMBL4071141 | 0.79 | AKR1B1 (0.49) | CA2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203708-A1 | NOVEL SUBSTITUTED-1-H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-08-13 | — | — | US | disclosed |
| US-20090203708-A1 | NOVEL SUBSTITUTED-1-H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203708-A1 | NOVEL SUBSTITUTED-1-H-QUINAZOLINE-2,4-DIONE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | HTR5A, HTR3B, HTR1A | CA2 4745/4885HPGD 1496/4885CYP1A2 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.